Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG7314 RD+ AVP SD · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dosing Period 1 | PLACEBO_COMPARATOR | - |
| Dosing Period 2 | ACTIVE_COMPARATOR | - |
| Dosing Period 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo RD + AVP SD | DRUG | Placebo (matching to study drug) repeat doses + intranasal AVP single dose |
| Placebo RD + Placebo SD | DRUG | Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose |
| RG7314 RD + AVP SD | DRUG | RG7314 repeat doses + intranasal AVP single dose |
Inclusion Criteria: * Right-handed, healthy non-smoker male adults, 18 to 45 years of age * A body mass index between 18 to 32 kg/m2 inclusive and total weight in the range of 50-100 kg * Participants and their partners of childbearing potential must use 2 methods of contraception, one of which mus...
RG7314 RD+ AVP SD is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 proof-of-mechanism trial in healthy male volunteers, evaluating its potential regulation of higher brain functions. The specific therapeutic indication for this asset has not been disclosed.
RG7314 RD+ AVP SD is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the Phase 1 study of the compound. No partnership or licensing arrangement for this asset has been disclosed.
RG7314 RD+ AVP SD is in Phase 1 development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
RG7314 RD+ AVP SD has been evaluated in one completed Phase 1 trial, NCT02205073. The study was a randomized, double-blind, placebo-controlled crossover trial of 32 healthy male participants in the Netherlands, designed as a proof-of-mechanism study of the compound's effects on higher brain functions.
RG7314 RD+ AVP SD has been studied in healthy male volunteers rather than in a patient population, and its target indication has not been disclosed. The completed Phase 1 trial, NCT02205073, examined the compound's potential regulation of higher brain functions as a proof of mechanism.